Prot #J2T-MC-KGBI/DRM06-AD13: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Lebrikizumab Compared to Placebo in Participants 6 Months to <18 Years of Age with Moderate-to-Severe Atopic

Project: Research project

Project Details

StatusActive
Effective start/end date3/30/233/30/26

Funding

  • Lilly USA, LLC (Prot #J2T-MC-KGBI/DRM06-AD13)